Date	:2022/7		
Your	Name:Jing	Jing Zhang	
			hTPO and rhIL-11 in the treatment of chemotherapy-
indu	iced thrombocytopenia i	n hematological tumor	s based on real-world data
Man	uscript number (if known):		
			relationships/activities/interests listed below that are
	-	-	ns any relation with for-profit or not-for-profit third
•	•	•	f the manuscript. Disclosure represents a commitment
	-		If you are in doubt about whether to list a
relat	ionship/activity/interest, it	is preferable that you do	so.
The f	following questions apply t	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
man	uscript only.		
Tha	outhow's valationships/activ	uitina/intanasta ahauld ha	defined breedly. For evenuels, if your many conjust montains
	-		defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
	ication, even if that medica	· · ·	
In ite	em #1 below, report all sup	port for the work reported	d in this manuscript without time limit. For all other items,
the t	ime frame for disclosure is	the past 36 months.	
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed) Time frame: Since the initia	al planning of the work
1	All support for the present	X None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	no time mint for this itelli.		<u> </u>
		Time frame: pas	t 36 months
2	Grants or contracts from	XNone	

X__None

_X__None

any entity (if not indicated

in item #1 above). Royalties or licenses

Consulting fees

3

4

5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
	testimony		
	,		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Plea	ase summarize the above co	nflict of interest in the fol	lowing box:

None

	e:2022/7		
You	r Name: Rui Zh	ao	
			TPO and rhIL-11 in the treatment of chemotherapy-
ind	aced thrombocytopenia i	n hematological tumors	based on real-world data
	uscript number (if known):	_	
rela part to tr	ted to the content of your n ies whose interests may be	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias.	relationships/activities/interests listed below that are any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment of you are in doubt about whether to list a so.
	following questions apply to uscript only.	o the author's relationship	s/activities/interests as they relate to the <u>current</u>
to th		nsion, you should declare a	efined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive me manuscript.
	em #1 below, report all sup time frame for disclosure is	· · · · · · · · · · · · · · · · · · ·	in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
<u></u>		Time frame: Since the initia	planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	

Consulting fees

__X__None

5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
	testimony		
	,		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Plea	ase summarize the above co	nflict of interest in the fol	lowing box:

None

Date	e:2022/7		
You	r Name:Fan Xia	a	
			TPO and rhIL-11 in the treatment of chemotherapy
ind	uced thrombocytopenia i	n hematological tumors	s based on real-world data
	nuscript number (if known):	_	
rela part to ti	ted to the content of your n ies whose interests may be	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias.	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply t uscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
to tl		nsion, you should declare	lefined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.
	em #1 below, report all sup time frame for disclosure is		l in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	I planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	: 36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	

Consulting fees

__X__None

5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
	testimony		
	,		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Plea	ase summarize the above co	nflict of interest in the fol	lowing box:

None

Date:	2022/7		
Your Name:	Yue L	i	
Manuscript Title	: Cost-eff	ectiveness analysis of r	hTPO and rhIL-11 in the treatment of chemotherapy-
		•	s based on real-world data
Manuscript num		C	
In the interest of	f transparency,	we ask you to disclose all	relationships/activities/interests listed below that are
related to the co	ntent of your n	nanuscript. "Related" mea	ans any relation with for-profit or not-for-profit third
parties whose in	terests may be	affected by the content of	f the manuscript. Disclosure represents a commitment
		<u>-</u>	If you are in doubt about whether to list a
relationship/acti	ivity/interest, i	t is preferable that you do	so.
The following qu	estions apply t	o the author's relationshi	ps/activities/interests as they relate to the current
manuscript only			
	-	-	defined broadly. For example, if your manuscript pertains
			all relationships with manufacturers of antihypertensive
medication, ever	n if that medica	ition is not mentioned in t	the manuscript.
		-	d in this manuscript without time limit. For all other items,
the time frame f	or disclosure is	the past 36 months.	
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initi	al planning of the work
	or the present	XNone	
	e.g., funding,		
-	study materials,		
medical writi	_		
processing ch	t for this item.		
No time iiiii	t ioi tilis itelli.		
1		1	l l

Time frame: past 36 months

_X__None

X__None

_X__None

2

3

4

Grants or contracts from

in item #1 above).
Royalties or licenses

Consulting fees

any entity (if not indicated

5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
	testimony		
	,		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Plea	ase summarize the above co	nflict of interest in the fol	lowing box:

None

Date:	2022/7
Your Name:	Rui-Wen Wang
Manuscript Title:	Cost-effectiveness analysis of rhTPO and rhIL-11 in the treatment of chemotherapy
induced thrombo	cytopenia in hematological tumors based on real-world data
	(if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-		Beijing Medicinovo Technology Co. Ltd., Beijing, China
	financial interests		

Please summarize the above conflict of interest in the following box:

Rui-Wen Wang is from Beijing Medicinovo Technology Co. Ltd., Beijing, China.		

Please place an "X" next to the following statement to indicate your agreement:

Date:_____2022/7_____

_X__None

Consulting fees

You	r Name:Xin Gu	an				
Mar	nuscript Title: Cost-effe	ectiveness analysis of rh	TPO and rhIL-11 in the treatment of chemotherapy-			
	induced thrombocytopenia in hematological tumors based on real-world data Manuscript number (if known):					
rela part to ti	ted to the content of your miles whose interests may be	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias.	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.			
	following questions apply to nuscript only.	o the author's relationship	s/activities/interests as they relate to the <u>current</u>			
to tl med In it	ne epidemiology of hyperter lication, even if that medica	nsion, you should declare a tion is not mentioned in th port for the work reported	lefined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive ne manuscript. In this manuscript without time limit. For all other items,			
		Name all entities with	Specifications/Comments			
		whom you have this	(e.g., if payments were made to you or to your			
		relationship or indicate none (add rows as	institution)			
		needed)				
		Time frame: Since the initia	planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	XNone				
	processing charges, etc.)					
	No time limit for this item.					
		T: f	25 months			
2	Grants or contracts from	Time frame: past X None	56 Months			
۷	any entity (if not indicated					
2	in item #1 above).	V Nana				
3	Royalties or licenses	XNone				

5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
	testimony		
	,		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Plea	ase summarize the above co	nflict of interest in the fol	lowing box:

None

Date:_____2022/7_____

X_None

_X__None

Royalties or licenses

Consulting fees

4

You	r Name:Jian-Gu	ıo Zhu		
Man	uscript Title: Cost-effe	ectiveness analysis of rh	TPO and rhIL-11 in the treatment of chemotherapy-	
induced thrombocytopenia in hematological tumors based on real-world data Manuscript number (if known):				
ivian	iuscript number (ir known):			
relat part to tr	ted to the content of your miles whose interests may be	nanuscript. "Related" mear affected by the content of ecessarily indicate a bias. I	relationships/activities/interests listed below that are as any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment f you are in doubt about whether to list a so.	
	following questions apply to uscript only.	o the author's relationship	s/activities/interests as they relate to the <u>current</u>	
to th		nsion, you should declare a	efined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive manuscript.	
	em #1 below, report all supp time frame for disclosure is	·	in this manuscript without time limit. For all other items,	
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		needed) Time frame: Since the initial	planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone		
		Time from a next	26 months	
2	Grants or contracts from	Time frame: past X None	36 Months	
-	any entity (if not indicated in item #1 above).			

5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
	testimony		
	,		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Plea	ase summarize the above co	nflict of interest in the fol	lowing box:

None

Date:_____2022/7_____

__X__None

4

Consulting fees

You	r Name:Ai-Xia	Ma	
Mar	nuscript Title: Cost-eff	ectiveness analysis of r	hTPO and rhIL-11 in the treatment of chemotherapy-
	uced thrombocytopenia in uscript number (if known):	O	rs based on real-world data
rela part to ti	ted to the content of your n ies whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment of the same in doubt about whether to list a so.
	following questions apply touscript only.	o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
to tl		nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.
	em #1 below, report all sup time frame for disclosure is		d in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your institution)
		relationship or indicate none (add rows as	institution)
		needed)	
		Time frame: Since the initia	al planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
2	Grants or contracts from	Time frame: pas	it 36 months
2	any entity (if not indicated	XNone	
	in item #1 above).		
3	Royalties or licenses	XNone	

5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
	testimony		
	,		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Plea	ase summarize the above co	nflict of interest in the fol	lowing box:

None	